0000950170-24-006696.txt : 20240123
0000950170-24-006696.hdr.sgml : 20240123
20240123174635
ACCESSION NUMBER: 0000950170-24-006696
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240119
FILED AS OF DATE: 20240123
DATE AS OF CHANGE: 20240123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tregoning Kathleen
CENTRAL INDEX KEY: 0001830764
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 24553697
MAIL ADDRESS:
STREET 1: C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
STREET 2: 131 DARTMOUTH STREET SUITE 502
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
ownership.xml
4
X0508
4
2024-01-19
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001830764
Tregoning Kathleen
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02141
false
true
false
false
See Remarks
false
Restricted Stock Units
2024-01-19
4
A
false
59171
0.00
A
Common Stock
59171
59171
D
The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date.
Title: Chief Corporate Affairs Officer
/s/ Mark Bodenrader, as Attorney-in-Fact
2024-01-23